期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿瑞匹坦的用药风险与合理应用 被引量：7

Risk and rational use of aprepitant
下载PDF
导出
摘要 通过回顾国内外近十年来有关阿瑞匹坦临床应用的文献报道,分析阿瑞匹坦的不良反应(ADR)与临床应用情况,为临床合理用药提供理论参考。阿瑞匹坦临床疗效较好,其常见ADR涉及胃肠道和神经系统。鉴于阿瑞匹坦的ADR和用药特点,临床医师及药师应重视阿瑞匹坦的合理用药,保证患者用药安全。 The adverse drug reaction（ADR） and clinical application of aprepitant were analyzed by reviewing literature related to aprepitant at home and abroad in the past ten years. Aprepitant showed a good curative effect in clinic. The common ADR of aprepitant were gastrointestinal reaction and neurotoxicity. Considering the ADR and drug administering characteristics of aprepitant, physicians and pharmacists should pay more attention to rational use of aprepitant in order to ensure drug safety of patients.
作者 裴丽 罗艳 黄显金 王丽伟 刘京伟
机构地区 解放军总医院第一附属医院药剂药理科
出处 《中国药物应用与监测》 CAS 2015年第5期310-312,318,共4页 Chinese Journal of Drug Application and Monitoring
基金 "十二五"国家科技支撑计划子课题(2013BAI06B04)
关键词 阿瑞匹坦 药品不良反应 合理用药 安全用药 临床评价 Aprepitant Adverse drug reaction Rational drug use Safe medication Clinical evaluation
分类号 R975 [医药卫生—药品]
  • 相关文献

参考文献22

  • 1Ruhlmann CH, Herrstedt J. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting[J]. Expert Opin Drug Saf, 2011, 10(3): 449-462.
  • 2Sankhala KK, Pandya DM, Sarantopoulos J, et al. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant[J]. Expert Opin Drug Metab Toxicol, 2009, 5(12): 1607-1614.
  • 3Warr D. The neurokininl receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy[J]. Expert Opin Pharmaeother, 2006, 7(12): 1653-1658.
  • 4Flemm LA. Aprepitant for chemotherapy-induced nausea and vomiting[J]. Clin J Oncol Nurs, 2004, 8(3): 303-306.
  • 5Hamada S, Hinotsu S, Kawai K, et al. Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy[J]. Support Care Cancer, 2014, 22(8): 2161-2166.
  • 6Gao HF, Liang Y, Zhou NN, et al. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy[J]. Intern Med J, 2013, 43(1): 73-76.
  • 7Choi CH, Kim MK, Park JY, et al. Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy- induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin[J]. Support Care Cancer, 2014, 22(5): 1181-1187.
  • 8Howell JE, Szabatura AH, Hatfield SA, et al. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant[J]. J Oncol Pharm Pract, 2008, 14(3): 157-162.
  • 9方振威,翟所迪.阿瑞吡坦防治化疗致恶心呕吐的Meta分析[J].北京大学学报（医学版）,2010,42(6):756-763. 被引量：19
  • 10Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting[J]. Ann Pharmacother, 2005, 39(1): 77-85.

二级参考文献20

  • 1张晓静,张频.肿瘤化疗所致恶心呕吐的发生机制和药物治疗的研究进展[J].癌症进展,2006,4(4):348-354. 被引量：129
  • 2Hiekok JT,Roscoe JA,Morrow GR,et al.Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics:a University of Rochester James P.Wilmot Cancer Center Community Clinical Oneology Program Study of 360 cancer patients treated in the community[J].Cancer,2003,97(11):2880-2886.
  • 3Jordan K,Schmoll HJ,Aapro MS.Compamtive activity ofantiemetic drugs[J].Crit Rev oncol Hematol,2007,61(2):162-175.
  • 4Grunberg SM,Deuson RR,Mavros P.et al.Incidence of chemotherapy-induced nausea and emesis after modern antiemetics[J].Cancer,2004,100(10):2261-2268.
  • 5Massaro AM,Lenz KL.Aprepitant:A novel antiemetic for chemotherapy-induced nausea and vomiting[J].Ann Pharmacother,2005.39(1):77-85.
  • 6Warr DG,Hesketh PJ,Gralla RJ.et al.Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenie chemotherapy[J].J Clin Oneol,2005,23(12):2822-2830.
  • 7National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology:Antiemesis,2nd,2010[M/OL].(2010-07-04)[2010-08-10].http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf.
  • 8Roila F,Hesketh PJ,Herrstedt J.Prevention of chemotherapyand radiotherapy-induced emesis:results of the 2004 Perugia International Antiemetic Consemus Conference[J].Ann Oncol,2006,17(1):20-28.
  • 9Kris MG,Hesketh PJ,Somerfield MR,et al.American Society of Clinical Oneology guideline for antiemetics in oncology:update 2006[J].J Clin Oncol,2006,24(18):2932-2947.
  • 10Yeo W,Mo FK,Suen JJ,et al.A randomized study of aprepirant,ondansetron and dexamethasone for chemotherapy-induced naugea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy[J].Breast Cancer Res Treat,2009,113(3):529-535.

共引文献18

同被引文献51

  • 1吴渊文,朱有华,杨军昌,鲁可权,张明,高晓刚,张纯.HCA-Ⅱ肾保存液对肾脏低温保存效果的实验研究[J].第二军医大学学报,2004,25(8):852-854. 被引量：5
  • 2刘雨村,张洪英,刘丽萍,彭其玉.制霉菌素甘油预防口腔真菌感染的临床观察[J].中华医院感染学杂志,2004,14(6):646-647. 被引量：16
  • 3陈文艳,熊建萍.肿瘤缺氧及其靶向治疗研究进展[J].国际肿瘤学杂志,2006,33(1):8-11. 被引量：6
  • 4聂映,毕小玲,尤启冬.阿瑞吡坦[J].中国新药杂志,2006,15(3):238-239. 被引量：16
  • 5赵忠斌,魏振平,芮伟.化疗止吐临床治疗药物新进展[J].世界临床药物,2006,27(8):480-484. 被引量：35
  • 6Hickok JT1, Roscoe JA, Morrow GR, et al. Fitch TR Nausea and emesisremain significant problems of chemotherapy despite prophylaxis with5-hydroxytryptamine-3 antiemetics: a University of Rochester James P.Wilmot Cancer Center Community Clinical Oncology Program Study of360 cancer patients treated in the community[J]. Cancer. 2003, 97(11):2880-2886.
  • 7Gralla RJ1, de Wit R, Herrstedt J. Antiemetic efficacy of the neurokinin-1antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid inpatients receiving anthracyclines or cyclophosphamide in addition to highdosecisplatin: analysis of combineddata from two Phase III randomizedclinical trials[J]. Cancer, 2005, 104(4): 864-868.
  • 8Fujita K. Cytochrome P450 and anticancer drugs [J]. Curr Drug Metab,2006, 7(1): 23-37.
  • 9Uchida M1, Kato K, Ikesue H, et al. Efficacy and safety of aprepitant inallogeneic hematopoietic stem cell transplantation[J]. Pharmacotherapy,2013, 33(9): 893-901.
  • 10Uchida M1, Ikesue H, Kato K, et al. Antiemetic effectiveness and safetyof aprepitant in patients with hematologic malignancy receiving multidaychemotherapy[J]. Am J Health Syst Pharm, 2013, 70(4): 343-349.

引证文献7

二级引证文献37

中国药物应用与监测
2015年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部